Hematología y Hemoterapia

Resultados: 476
Tipo Título / Nombre Autor(es) Año
Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry Colmenares R, Álvarez N, Barragán E, Boluda B, Larrayoz MJ..., Bergua J, et al 2025
Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience Serrano J, Martínez-Cuadrón D, Gil C, Gil C, Gil C, Bernal T, et al 2025
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study Westin J, Tycel JP, Amitkumar M..., Bergua Burgués JM 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D..., Bergua Burgues JM, et al 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy Manubens A, Paiva B, Gutiérrez NC, , et al 2025
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study Boluda B, Rodríguez Viga R, Sargas C, Ayala R..., Bergua J 2025
Ketone Bodies Are Potential Prognostic Biomarkers in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results from the R2-GDP-GOTEL Trial Fernández-Castillejo S, Badia J, de la Cruz-Merino L, Martín Garcia-Sáncho A, Carnicero-González F..., Carnicero-González F, et al 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al 2025
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study Lloret-Madrid P, Boluda B, Martínez-López J, Bergua J, Rodriguez Arboli E, Labrador J, et al 2025